Illicit Stimulant Use in Humans Is Associated with a Long-Term Increase in Tremor

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Flavel, Stanley C ^a   Koch, Jenna D ^a   White, Jason M ^a   Todd, Gabrielle ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; ILLICIT DRUG; METHAMPHETAMINE; OPIATE; PSYCHEDELIC AGENT; SEDATIVE AGENT;

ABSTINENCE; ACCELEROMETRY; ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; FEMALE; FOURIER TRANSFORMATION; HUMAN; HUMAN EXPERIMENT; INDEX FINGER; MALE; MOVEMENT (PHYSIOLOGY); NORMAL HUMAN; REST; TREMOR;

ADOLESCENT; ADULT; AMPHETAMINES; CANNABIS; DRUG USERS; FEMALE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STREET DRUGS; TREMOR; YOUNG ADULT;

ANIMALIA; CANNABIS;

EID: 84871302742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052025     Document Type: Article

References (63)

1. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, et al. (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17: 309-312.
2. Hallett M, (1998) Overview of human tremor physiology. Mov Disord 13 (Suppl 3): 43-48.
3. Bauer LO, (1993) Motoric signs of CNS dysfunction associated with alcohol and cocaine withdrawal. Psychiatry Res 47: 69-77.
4. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, et al. (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav 29: 743-752.
5. McCann UD, Ridenour A, Shaham Y, Ricaurte GA, (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10: 129-138.
6. AIHW (2011) 2010 National Drug Strategy Household Survey report. Canberra: Australian Institute of Health and Welfare. 1-323 p.
7. AIHW (2005) Statistics on drug use in Australia 2004. Canberra: Australian Institute of Health and Welfare. Cat. No. PHE 62. 1-105 p.
8. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
9. Toomey R, Lyons MJ, Eisen SA, Xian H, Chantarujikapong S, et al. (2003) A twin study of the neuropsychological consequences of stimulant abuse. Arch Gen Psychiatry 60: 303-310.
10. Bousman CA, Cherner M, Emory KT, Barron D, Grebenstein P, et al. (2010) Preliminary evidence of motor impairment among polysubstance 3,4-methylenedioxymethamphetamine users with intact neuropsychological functioning. J Int Neuropsychol Soc 16: 1047-1055.
11. Cardoso F, Jankovic J, (1993) Movement disorders. Neurol Clin 11: 625-638.
12. Lundh H, Tunving K, (1981) An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry 44: 728-730.
13. Downes MA, Whyte IM, (2005) Amphetamine-induced movement disorder. Emerg Med Australas 17: 277-280.
14. Cardoso FE, Jankovic J, (1993) Cocaine-related movement disorders. Mov Disord 8: 175-178.
15. Factor SA, Sanchez-Ramos JR, Weiner WJ, (1988) Cocaine and Tourette's syndrome. Ann Neurol 23: 423-424.
16. Catalano G, Catalano MC, Rodriguez R, (1997) Dystonia associated with crack cocaine use. South Med J 90: 1050-1052.
17. Pascual-Leone A, Dhuna A, (1990) Cocaine-associated multifocal tics. Neurology 40: 999-1000.
18. Rossi S, Hallett M, Rossini PM, Pascual-Leone A, (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120: 2008-2039.
19. Wechsler D (1987) Wechsler Memory Scale- Revised. New York: Psychological Corporation.
20. Benton AL, Hamsher K (1983) Multilingual Aphasia Examination. Iowa City: AJA Associates.
21. Grigsby J, Kaye K, (1995) Alphanumeric sequencing and cognitive impairment among elderly persons. Percept Mot Skills 80: 732-734.
22. Wechsler D (1981) Wechsler Adult Intelligence Scale- Revised. New York: Psychological Corporation.
23. Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. San Antonio: The Psychological Corporation.
24. Vickers D, Nettelbeck T, Willson RJ, (1972) Perceptual indices of performance: the measurement of 'inspection time' and 'noise' in the visual system. Perception 1: 263-295.
25. Lyons KE, Pahwa R, (2008) Pharmacotherapy of essential tremor: an overview of existing and upcoming agents. CNS Drugs 22: 1037-1045.
26. Kear-Colwell JJ, Heller M, (1978) A normative study of the Wechsler Memory Scale. J Clin Psychol 34: 437-442.
27. Tombaugh TN, Kozak J, Rees L, (1999) Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol 14: 167-177.
28. Mittenberg W, Burton DB, Darrow E, Thompson GB, (1992) Normative data for the Wechsler Memory Scale-Revised: 25- to 34-year-olds. Psychol Assess 4: 363-368.
29. Mrazik M, Millis S, Drane DL, (2010) The oral trail making test: effects of age and concurrent validity. Arch Clin Neuropsychol 25: 236-243.
30. Freeman JS, Cody FW, Schady W, (1993) The influence of external timing cues upon the rhythm of voluntary movements in Parkinson's disease. J Neurol Neurosurg Psychiatry 56: 1078-1084.
31. McAuley JH, Marsden CD, (2000) Physiological and pathological tremors and rhythmic central motor control. Brain 123: 1545-1567.
32. Yamamoto BK, Bankson MG, (2005) Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit Rev Neurobiol 17: 87-117.
33. Sulzer D, Sonders MS, Poulsen NW, Galli A, (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406-433.
34. Benowitz NL, (1993) Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 72: 3-12.
35. Greco PG, Garris PA, (2003) In vivo interaction of cocaine with the dopamine transporter as measured by voltammetry. Eur J Pharmacol 479: 117-125.
36. Callaghan RC, Cunningham JK, Sajeev G, Kish SJ, (2010) Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 25: 2333-2339.
37. Vallbo AB, Wessberg J, (1993) Organization of motor output in slow finger movements in man. J Physiol 469: 673-691.
38. Farmer SF, (1998) Rhythmicity, synchronization and binding in human and primate motor systems. J Physiol 509: 3-14.
39. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
40. Mueller M, Yuan J, Maldonado Adrian C, McCann UD, et al. (2011) Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: implications for mechanisms of neurotoxicity. Synapse 65: 983-990.
41. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, et al. (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313: 422-431.
42. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, et al. (2001) 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154: 251-260.
43. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, et al. (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241: 338-345.
44. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, et al. (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276: 855-865.
45. Schmidt CJ, Taylor VL, (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36: 4095-4102.
46. Ricaurte GA, Martello AL, Katz JL, Martello MB, (1992) Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622.
47. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA, (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352: 1433-1437.
48. Kish SJ, Fitzmaurice PS, Chang LJ, Furukawa Y, Tong J, (2010) Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study. J Psychopharmacol 24: 281-284.
49. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, et al. (2002) The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26: 387-396.
50. Hatzidimitriou G, McCann UD, Ricaurte GA, (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107.
51. Baker SN, (2007) Oscillatory interactions between sensorimotor cortex and the periphery. Curr Opin Neurobiol 17: 649-655.
52. Rothwell JC, (1998) Physiology and anatomy of possible oscillators in the central nervous system. Mov Disord 13 (Suppl 3): 24-28.
53. Dafters RI, Duffy F, O'Donnell PJ, Bouquet C, (1999) Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology 145: 82-90.
54. Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, et al. (2001) Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Hum Brain Mapp 14: 152-165.
55. Priori A, Bertolasi L, Berardelli A, Manfredi M, (1995) Acute dystonic reaction to ecstasy. Mov Disord 10: 353.
56. Cosentino C, (2004) Ecstasy and acute dystonia. Mov Disord 19: 1386-1387.
57. Demirkiran M, Jankovic J, Dean JM, (1996) Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 19: 157-164.
58. Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, et al. (1998) A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 20: 467-476.
59. Raethjen J, Lemke MR, Lindemann M, Wenzelburger R, Krack P, et al. (2001) Amitriptyline enhances the central component of physiological tremor. J Neurol Neurosurg Psychiatry 70: 78-82.
60. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, et al. (2003) Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375-384.
61. Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, et al. (2009) Brain serotonin transporter binding in former users of MDMA ('ecstasy'). Br J Psychiatry 194: 355-359.
62. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G, (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci 15: 5476-5485.
63. Morefield KM, Keane M, Felgate P, White JM, Irvine RJ, (2011) Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction 106: 1293-1300.